The study partner requirement in preclinical Alzheimers disease trials

阿尔茨海默病临床前试验中研究伙伴的要求

基本信息

  • 批准号:
    9373717
  • 负责人:
  • 金额:
    $ 22.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-15 至 2019-05-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract Preclinical Alzheimer's disease clinical trials enroll cognitively normal participants who are willing to undergo disease biomarker testing, learn the results, and take an investigational drug (or placebo) if those results indicate that they are at increased risk for disease. Like traditional trials in Alzheimer's disease dementia, these trials require participants to enroll with a study partner, a person who can attend visits with the participant and report about any changes in the participant's cognitive or functional ability. Like traditional trials in Alzheimer's disease dementia, these trials face logistical challenges related to difficult recruitment. We recently showed that the requirement for a participant to learn their Alzheimer's disease biomarker status was not a barrier to successful recruitment. In contrast, the requirement of enrolling with a study partner was a significant barrier to participation for many potential enrollees. We also observed results that suggested that the study partner barrier was related to the requirement of biomarker testing and disclosure. This project will further investigate the study partner role in preclinical Alzheimer's disease clinical trials. First, we will explore the ethical implications of the study partner requirement, specifically whether this requirement is a barrier to enrollment because participants are unwilling to share their biomarker results with others. Second, we examine the scientific need for study partners, by measuring informants' accuracy and precision in assessing cognitive performance, predicting cognitive decline, and recognizing subtle changes in cognition, and comparing to participants' abilities to perform these roles themselves. These studies will provide valuable data toward improving preclinical AD trial protocol designs, assisting investigators making decisions around 1) whether to require study partners, 2) who is qualified to fill this role, and 3) how participants should be protected against potential stigma related to their eligibility.
项目总结/摘要 临床前阿尔茨海默病临床试验招募愿意接受治疗的认知正常参与者 疾病生物标志物检测,了解结果,并采取研究药物(或安慰剂),如果这些结果 表明他们患病的风险增加。就像阿尔茨海默病痴呆症的传统试验一样, 试验要求参与者与研究伙伴一起登记,研究伙伴是可以与参与者一起参加访视的人, 报告参与者认知或功能能力的任何变化。就像阿尔茨海默病的传统试验一样 然而,这些试验面临着与招募困难有关的后勤挑战。我们最近展示了 要求参与者了解他们的阿尔茨海默病生物标志物状态并不是一个障碍, 成功招聘。相比之下,与研究伙伴一起入组的要求是一个重大障碍, 许多潜在的参与者。我们还观察到的结果表明, 障碍与生物标志物检测和披露的要求有关。 该项目将进一步研究研究伙伴在临床前阿尔茨海默病临床试验中的作用。第一、 我们将探讨研究伴侣要求的伦理含义,特别是这一要求是否 因为参与者不愿意与他人分享他们的生物标志物结果,所以成为入组的障碍。第二、 我们通过测量被调查者在以下方面的准确性和精确性来研究对学习伙伴的科学需求: 评估认知表现,预测认知能力下降,识别认知能力的细微变化, 并与参与者自己扮演这些角色的能力进行比较。 这些研究将为改善临床前AD试验方案设计提供有价值的数据, 研究者决定1)是否需要研究伙伴,2)谁有资格担任这一角色, 以及3)应如何保护参与者免受与其资格有关的潜在耻辱。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daniel L Gillen其他文献

Daniel L Gillen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daniel L Gillen', 18)}}的其他基金

Statistical Methods for Alzheimer's Research
阿尔茨海默病研究的统计方法
  • 批准号:
    10522647
  • 财政年份:
    2022
  • 资助金额:
    $ 22.25万
  • 项目类别:
Recruiting and retaining participants from disadvantaged neighborhoods in registries
在登记处招募和留住弱势社区的参与者
  • 批准号:
    10614609
  • 财政年份:
    2022
  • 资助金额:
    $ 22.25万
  • 项目类别:
Recruiting and retaining participants from disadvantaged neighborhoods in registries
在登记处招募和留住弱势社区的参与者
  • 批准号:
    10447533
  • 财政年份:
    2022
  • 资助金额:
    $ 22.25万
  • 项目类别:
Core C-Data Management & Statistics Core
核心 C 数据管理
  • 批准号:
    10188383
  • 财政年份:
    2020
  • 资助金额:
    $ 22.25万
  • 项目类别:
Core C-Data Management & Statistics Core
核心 C 数据管理
  • 批准号:
    10378029
  • 财政年份:
    2020
  • 资助金额:
    $ 22.25万
  • 项目类别:
Core C-Data Management & Statistics Core
核心 C 数据管理
  • 批准号:
    9922102
  • 财政年份:
    2020
  • 资助金额:
    $ 22.25万
  • 项目类别:
Core C-Data Management & Statistics Core
核心 C 数据管理
  • 批准号:
    10582628
  • 财政年份:
    2020
  • 资助金额:
    $ 22.25万
  • 项目类别:
Bioinformatics and Data Management Core
生物信息学和数据管理核心
  • 批准号:
    9205191
  • 财政年份:
    2017
  • 资助金额:
    $ 22.25万
  • 项目类别:
Neuroimaging biomarkers for cognitive decline in elderly with amyloid pathology
淀粉样蛋白病理老年人认知能力下降的神经影像生物标志物
  • 批准号:
    10160735
  • 财政年份:
    2017
  • 资助金额:
    $ 22.25万
  • 项目类别:
Neuroimaging biomarkers for cognitive decline in elderly with amyloid pathology
淀粉样蛋白病理老年人认知能力下降的神经影像生物标志物
  • 批准号:
    9311342
  • 财政年份:
    2017
  • 资助金额:
    $ 22.25万
  • 项目类别:

相似海外基金

I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    $ 22.25万
  • 项目类别:
    Standard Grant
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    $ 22.25万
  • 项目类别:
    Operating Grants
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    $ 22.25万
  • 项目类别:
    Grant for R&D
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    $ 22.25万
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    $ 22.25万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 22.25万
  • 项目类别:
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    $ 22.25万
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    $ 22.25万
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    $ 22.25万
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 22.25万
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了